Targeting resistant subpopulations of CSCs in GBM has been attempted in the past using drugs against PKCε, AKT and XIAP [33], PTEN/PI3K/Akt [34] and Hedgehog/Gli [35] pathway but have not yet progressed into clinical trial. The gene discussed is XIAP; the disease is glioblastoma.